4D Molecular Therapeutics, Inc. Stock News

EMERYVILLE, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in the 11 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16 th . Details of the fireside chat are as follows:

EMERYVILLE, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) --  4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted ge

4D Molecular Therapeutics Inc (NASDAQ: FDMT ) has … Full story available on Benzinga.com

4D Molecular Therapeutics (FDMT) reported updated interim data from the ongoing phase 1/2 trial of 4D-310 in patients with Fabry disease.Following 4D-310 infusion, mean serum AGA

The U.S. IPO market was red-hot in 2021. The total number of traditional U.S. IPOs hit its highest level since the dot-com boom in the late 1990s, while total IPO deal value reached record levels la

4D Molecular Therapeutics Inc (FDMT) shares closed today at 1.0% above its 52 week low of $18.57, giving the company a market cap of $602M. The stock is currently down 14.5% year-to-date, down 57.6% over the past 12 months, and down 53.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 56.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 811.1% The company's stock price performance over the past 12 months lags the peer average by 91.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

4D Molecular Therapeutics (FDMT) said the the first patient was dosed in a phase 1/2 trial of its gene therpay 4D-150 for neovascular age-related macular degeneration (wet AMD), a type

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) was the target of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 880,000 shares, a decrease of 25.4% from the November 15th total of 1,180,000 shares. Based on an average trading volume of 259,800 shares, the short-interest ratio is presently 3.4 []

4D Molecular Therapeutics (NASDAQ:FDMT) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a report released on Wednesday, Zacks.com reports. The brokerage presently has a $23.00 target price on the stock. Zacks Investment Researchs target price would suggest a potential upside of 10.79% from the companys current price. According []

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) gapped up before the market opened on Tuesday . The stock had previously closed at $21.42, but opened at $22.02. 4D Molecular Therapeutics shares last traded at $22.55, with a volume of 1,131 shares traded. Separately, Zacks Investment Research raised 4D Molecular Therapeutics from a hold rating to []

Zacks Investment Research upgraded shares of 4D Molecular Therapeutics (NASDAQ:FDMT) from a hold rating to a buy rating in a report published on Tuesday, Zacks.com reports. They currently have $24.00 price target on the stock. According to Zacks, 4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted []

State Street Corp increased its holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 54.9% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 165,492 shares of the companys stock after buying an additional 58,659 shares during the period. State Street Corps holdings in 4D Molecular Therapeutics were []

EMERYVILLE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in a fireside chat at the Evercore ISI HealthCONx 2021 Conference. The fireside chat will take place on Thursday, December 2 nd , 2021 at 10:55 a.m. ET.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) shares gapped down prior to trading on Friday . The stock had previously closed at $24.15, but opened at $22.79. 4D Molecular Therapeutics shares last traded at $22.79, with a volume of 612 shares changing hands. Separately, Zacks Investment Research raised 4D Molecular Therapeutics from a hold rating to a []

The stock price of 4D Molecular Therapeutics Inc (NASDAQ: FDMT) increased by over 13% during intraday trading today. This is why it happened.